Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Drugs · 2025-01 · 85 (1) · 67-85
DOI: 10.1007/s40265-024-02115-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 13.11.2024. Verfasst von Ole Haagen Nielsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology D112, Herlev Hospital, University of Copenhagen, Borgmester Ib Juuls Vej 1, 2730 Herlev, Copenhagen, Denmark. ole.haag…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Antibodies, Monoclonal, Biological Products, Antibodies. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 199 Literaturangaben. Gefördert von: Memorial Foundation of Solveig Høymann Jacobsen, NIDDK NIH HHS, Doris Duke Charitable Foundation.
Abstract (Originalsprache)
The introduction of tumor necrosis factor inhibitors has led to a paradigm shift in the management of inflammatory bowel disease (IBD). The subsequent introduction of both anti-integrins and cytokine blockers has since expanded the biologic armamentarium. However, immunogenicity, defined as the production of anti-drug antibodies (ADAs) to the prescribed biopharmaceutical, means a significant fraction of patients exposed to biologic agents will experience a secondary loss of response to one or more of the drugs. In clinical settings, immunogenicity may be caused by several factors, both patient related (e.g., underlying chronic disease, systemic immune burden, including previous biologic therapy failure, and [epi]genetic background) and treatment related (e.g., dose and administration regimens, drug physical structure, photostability, temperature, and agitation). Here, we outline these elements in detail to enhance biopharmaceutical delivery and therapy for patients with IBD. Moreover, concurrent immunomodulator medication may reduce the risks of ADA generation, especially when using the chimeric drug infliximab. Summarizing the latest developments and knowledge in the field, this review aims to provide strategies to prevent ADA production and information on managing non-responsiveness or loss of response to biologics. Better understanding of the molecular mechanisms underlying the formation of ADAs and the critical factors influencing the immunogenicity of biopharmaceuticals may lead to improved health outcomes in the IBD community that may benefit both the individual patient and society through lower healthcare expenses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology D112, Herlev Hospital, University of Copenhagen, Borgmester Ib Juuls Vej 1, 2730 Herlev, Copenhagen, Denmark. ole.haagen.nielsen@regionh.dk.
- Department of Gastroenterology D112, Herlev Hospital, University of Copenhagen, Borgmester Ib Juuls Vej 1, 2730 Herlev, Copenhagen, Denmark.
- Department of Gastroenterology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
- Department of Gastroenterology & Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA.
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Förderung
- Memorial Foundation of Solveig Høymann Jacobsen
- NIDDK NIH HHS
- Doris Duke Charitable Foundation
- Chan Zuckerberg Initiative
Zitieren
APA
Nielsen, O. H., Hammerhøj, A., Ainsworth, M. A., Gubatan, J., & D'Haens, G. (2025). Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations. Drugs, 85(1), 67-85. https://doi.org/10.1007/s40265-024-02115-3
Vancouver
Nielsen OH, Hammerhøj A, Ainsworth MA, Gubatan J, D'Haens G. Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations. Drugs. 2025;85(1):67-85. doi:10.1007/s40265-024-02115-3
BibTeX
@article{Nielsen2025,
author = {Nielsen, Ole Haagen and Hammerhøj, Alexander and Ainsworth, Mark Andrew and Gubatan, John and D'Haens, Geert},
title = {Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations},
journal = {Drugs},
year = {2025},
volume = {85},
number = {1},
pages = {67--85},
doi = {10.1007/s40265-024-02115-3}
}
EUVIMED